Recap: Neos Therapeutics Q2 Earnings

Shares of Neos Therapeutics NEOS rose 4.2% in pre-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share decreased 37.50% over the past year to ($0.11), which beat the estimate of ($0.13).

Revenue of $13,133,000 declined by 16.05% year over year, which beat the estimate of $12,170,000.

Guidance

Neos Therapeutics hasn't issued any earnings guidance for the time being.

Neos Therapeutics hasn't issued any revenue guidance for the time being.

How To Listen To The Conference Call

Date: Aug 10, 2020

Time: 08:30 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/zyx7gcty

Recent Stock Performance

52-week high: $2.15

52-week low: $0.60

Price action over last quarter: down 10.70%

Company Profile

Neos Therapeutics Inc is a pharmaceutical company, engaged in the development, manufacture, and commercialization of products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technologies. The product portfolio of the company includes Methylphenidate XR-ODT and Amphetamine XR oral suspension commonly prescribed medicine for the treatment of ADHD. In addition, it also manufactures and markets generic Tussionex, a hydrocodone polistirex and chlorpheniramine polistirex XR liquid suspension product indicated for the relief of cough. Geographically, it operates through the United States and derives revenue through the sale of products.